ADC Therapeutics SA (ADCT) Tops Q4 EPS by 38c

ADC Therapeutics SA (NYSE: ADCT) reported Q4 EPS of ($0.10), $0.38 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $19.8 million versus the consensus estimate of $55.8 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c